Importantly, two key preclinical studies recently demonstrated that inhibition of RANKL significantly suppressed Brca1-mammary carcinogenesis suggesting that this may be a novel target for prevention in women at a high risk of developing breast cancer due to an inherited BRCA1 mutation [8, 9]. The gene discussed is BRCA1; the disease is breast carcinoma.